AL amyloidosis is a rare and serious disease caused by abnormal plasma cells in the bone marrow that produce misfolded amyloid proteins. These proteins build up in vital organs, such as the heart, kidneys, and liver, leading to progressive, multi-organ damage. It is also associated with high mortality rates. DARZALEX FASPRO, developed by Johnson & Johnson, is the first and only approved treatment for patients with newly diagnosed AL amyloidosis. However, there are no FDA-approved therapies for relapsed/refractory AL amyloidosis patients.
The company we are profiling today is also developing a cell therapy for AL Amyloidosis - Immix Biopharma Inc. (IMMX).
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.